AXL degradation in combination with EGFRTKI can delay and overcome acquired resistance in human nonsmall cell lung cancer cells

AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells

05:47 EDT 2 May 2019 | Nature Publishing

More From BioPortfolio on "AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells"